Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 September 2024 | Story André Damons | Photo André Damons
Prof Martin Nyaga – Associate Professor and Head of the University of the Free State (UFS) Next Generation Sequencing Unit (UFS-NGS) – recently obtained a B3 rating from the National Research Foundation (NRF).

Prof Martin Nyaga – Associate Professor and Head of the University of the Free State (UFS) Next Generation Sequencing (NGS) Unit – recently obtained an NRF B3 rating from the National Research Foundation (NRF), which is not only testament to his research prowess, but also demonstrates his unwavering commitment to academic excellence.

Prof Nyaga made a significant improvement from his previous NRF Y2 rating (categorised as a promising young researcher). His new B3 rating is assigned to a researcher who enjoys considerable international recognition by their peers for the high quality and impact of their recent research output.

“It is an incredibly thrilling experience to attain the esteemed NRF rating in the B category. Accomplishing the NRF B3 rating satiates an enormous sense of being appreciated and acknowledged individually and as an academic at the UFS. This acknowledgement emphasises the high quality of the research that I do and provides immense motivation to continue mentoring upcoming and emerging researchers in the field of molecular virology,” says Prof Nyaga.

Research output

According to him, this recognition serves as motivation to become an NRF A-rated researcher in the next rating cycle. “I am optimistic that I can meet the minimum threshold to be among the highly esteemed NRF A-rated researchers who are internationally recognised as leading scholars in their field of specialisation for their high-quality research and wide impact.”

Prof Nyaga, who is affiliated to the Division of Virology within the Faculty of Health Sciences, has an exponential trajectory in research output dissemination in reputable international conference presentations and scientific/medical journals such as Nature, Nature Medicine, Nature Communications, and Science, among other quantile 1 journals, with significant citations (3 337 times, h-index 20 and i-10 index 32). He has demonstrated unwavering commitment to academic excellence and has made significant strides within his niche research area of whole genome sequencing and metagenomics of enteric and respiratory viruses. He has not only successfully collaborated with eminent researchers both within and outside the university and globally, but his interdisciplinary research approach has led to groundbreaking studies that address complex issues from multiple perspectives.

Prof Nyaga has applied his expertise to address real-world challenges. One notable example is his involvement in community-based projects and public outreach and education. He has organised and participated in various workshops, seminars, and public lectures aimed at disseminating knowledge and raising awareness about important issues in the field of enteric and respiratory pathogen genomics. His efforts have strengthened the ties between the UFS and the broader community, enhancing the impact and visibility of the institution.

Support by the UFS

“Achieving this rating not only required self-driven research-enhancement discipline, networking, and implementation of novel concepts to enhance my NRF research rating from Y to B, but I also received substantial support from my affiliate institution, especially the Faculty of Health Sciences and the Directorate of Research and Development (DRD).”

“The UFS has put in place amazing policies and career development strategies to ensure that focused Y-rated researchers have the opportunity to become established researchers within one rating cycle of five years – a reality that I immensely thank God for enabling me to attain,” says Prof Nyaga.

These programmes include, among others, the Transforming the Professoriate Mentoring Programme, where he was part of the first cohort of members recruited in 2019.

Prof Nyaga, who has supervised/co-supervised seven PhDs and more than 20 master’s and honours postgraduates to graduation, also serves in various leadership roles, including Chairman for the Africa Centres for Disease Control and Prevention (ACDC) Pathogen Genomics Initiative (PGI), Vaccine-Preventable Diseases (VPD) Focus Group (FG), and Director of the WHO Collaborating Centre for VPD Surveillance and Pathogen Genomics. His ability to instigate and inspire as the team lead and his strategic vision for the UFS-NGS Unit are key factors in the successful execution of numerous initiatives. He is a strong advocate for diversity, equity, and inclusion, and his efforts have created a more inclusive and welcoming environment for his peers and students from diverse backgrounds.

Future

He plans to undertake future research that has an impact on the national health systems and to establish himself as an international leader in his niche research area. “I hope to create a vibrant association between research and national development goals and to have a transformative effect on my area of research in a way that can influence policy by addressing national and international challenges within global knowledge innovation,” says Prof Nyaga.

His continuing research involves the use of next generation sequencing to decipher the viral component of the respiratory and enteric milieu and accentuate the critical need to define the complete spectrum of disease-causing viruses. Several previously known and unknown viruses have been detected, including viruses with previously unrecognised tropism.

Additionally, whole genome sequencing of important respiratory viruses, such as the respiratory syncytial virus (RSV) (as part of the respiratory niche) and rotavirus (as part of the enteric niche), is being performed simultaneously for different countries, including South Africa, Zambia, Rwanda, Kenya, Cameroon, Mozambique, and Malawi, to enhance the genomic surveillance of specific respiratory and enteric viruses of interest.

The overall goal is to identify novel pathogens responsible for human viral diseases and to create a flexible and highly effective system for the rapid identification and analysis of emerging or re-emerging agents. This will serve four purposes: (i) improve preparedness for outbreaks, (ii) characterise new viruses, (iii) identify additional new pathogenic viruses, and (iv) provide new understanding of the human respiratory and enteric virome.

“Viruses that appear to be relevant will be prioritised to elucidate specific targets for rapid diagnostics using panels developed from the antigenic sites of the generated genomes, and immune mechanisms used to develop antiviral interventions such as drugs and vaccines,” explains Prof Nyaga.

Prof Vasu Reddy, Deputy Vice-Chancellor: Research and Internationalisation, commented: “The rating bears testimony to the incredibly important and impactful work that Prof Nyaga is undertaking. The solid international footprint of his publications and their citations also confirm the relevance and currency of his cutting-edge work. The UFS is extremely proud of this signal achievement, and we wish him well with his work in the years ahead.”

News Archive

Research contributes to improving quality of life for cancer patients
2016-11-21

Description: Inorganic Chemistry supervisors  Tags: Inorganic Chemistry supervisors

Inorganic Chemistry supervisors in the Radiopharmacy
Laboratory during the preparation of a typical complex
mixture to see how fast it reacts. Here are, from the left,
front: Dr Marietjie Schutte-Smith, Dr Alice Brink
(both scholars from the UFS Prestige
Scholar Programme), and Dr Truidie Venter (all three
are Thuthuka-funded researchers).
Back: Prof André Roodt and Dr Johan Venter.
Photo: Supplied

Imagine that you have been diagnosed with bone cancer and only have six months to live. You are in a wheelchair because the pain in your legs is so immense that you can’t walk anymore – similar to a mechanism eating your bones from the inside.

You are lucky though, since you could be injected with a drug to control the pain so effective that you will be able to get out of the wheelchair within a day-and-a-half and be able to walk again. Real-life incidents like these provide intense job satisfaction to Prof André Roodt, Head of Inorganic Chemistry at the University of the Free State (UFS). The research, which is conducted by the Inorganic Group at the UFS, contributes greatly to the availability of pain therapy that does not involve drugs, but improves the quality of life for cancer patients.

The research conducted by the Inorganic Group under the leadership of Prof Roodt, plays a major role in the clever design of model medicines to better detect and treat cancer.

The Department of Chemistry is one of approximately 10 institutions worldwide that conducts research on chemical mechanisms to identify and control cancer. “The fact that we are able to cooperate with the Departments of Nuclear Medicine and Medical Physics at the UFS, the Animal Research Centre, and other collaborators in South Africa and abroad, but especially the methodology we utilise to conduct research (studying the chemical manner in which drugs are absorbed in cancer as well as the time involved), enhances the possibility of making a contribution to cancer research,” says Prof Roodt.

Technique to detect cancer spots on bone
According to the professor, there are various ways of detecting cancer in the body. Cancer can, inter alia, be identified by analysing blood, X-rays (external) or through an internal technique where the patient is injected with a radioactive isotope.

Prof Roodt explains: “The doctor suspects that the patient has bone cancer and injects the person with a drug consisting of an isotope (only emits X-rays and does no damage to tissue) that is connected to a phosphonate (similar to those used for osteoporosis). Once the drug is injected, the isotope (Technetium-99m) moves to the spot on the bone where the cancer is located. The gamma rays in the isotope illuminate the area and the doctor can see exactly where treatment should be applied. The Technetium-99m has the same intensity gamma rays as normal X-rays and therefore operates the same as an internal X-ray supply.” With this technique, the doctor can see where the cancer spots are within a few hours.

The same technique can be used to identify inactive parts of the brain in Alzheimer patients, as well as areas of the heart where there is no blood supply or where the heart muscle is dead.

Therapeutic irradiation of cancer
For the treatment of pain connected with cancer, the isotope Rhenium-186 is injected. Similar to the manner in which the Technetium-99m phosphonate compound is ingested into the body, the Rhenium-186 phosphonate travels to the cancer spots. Patients thus receive therapeutic irradiation – a technique known as palliative therapy, which is excellent for treating pain. A dosage of this therapy usually lasts for about two months.

The therapy is, however, patient specific. The dosages should correspond with the occurrence and size of cancer spots in the patient’s body. First, the location of the cancer will be determined by means of a technetium scan. After that, the size of the area where the cancer occurs has to be determined. The dosage for addressing total pain distribution will be calculated according to these results.

Technique to detect cancer spots on soft tissue
Another technique to detect cancer as spots on bone or in soft tissue and organs throughout the body is by utilising a different type of irradiation, a so-called PET isotope. The Fluor-18 isotope is currently used widely, and in Pretoria a machine called a cyclotron was produced by Dr Gerdus Kemp, who is a former PhD graduate from the Inorganic Research Group. The F-18 is then hidden within a glucose molecule and a patient will be injected with the drug after being tranquillised and after the metabolism has been lowered considerably. The glucose, which is the ‘food' that cancer needs to grow, will then travel directly to the cancer area and the specific area where the cancer is located will thus be traced and ‘illuminated’ by the Fluor-18, which emits its own 'X-rays'.

In the late 80s, Prof Roodt did his own postdoctoral study on this research in the US. He started collaborating with the Department of Nuclear Medicine at the UFS in the early 90s, when he initiated testing for this research.

Through their research of more than 15 years, the Inorganic Group in the Department of Chemistry has made a major contribution to cancer research. Research on mechanisms for the detection of cancer, by designing new clever chemical agents, and the chemical ways in which these agents are taken up in the body, especially contributes to the development in terms of cancer therapy and imaging, and has been used by a number of hospitals in South Africa.

The future holds great promise
Prof Roodt and his team are already working on a bilateral study between the UFS and Kenya. It involves the linking of radio isotopes, as mentioned above, to known natural products (such as rooibos tea), which possess anti-cancer qualities.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept